Fig. 2From: Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort studyProgression-free survival of mCRPC patients treated with AAPBack to article page